Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 5
2015 8
2016 8
2017 6
2018 6
2019 8
2020 4
2021 2
2022 4
2023 3
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean oncolytic biotech[Affiliation] (100 results)?
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG. Evgin L, et al. Sci Transl Med. 2022 Apr 13;14(640):eabn2231. doi: 10.1126/scitranslmed.abn2231. Epub 2022 Apr 13. Sci Transl Med. 2022. PMID: 35417192 Free PMC article.
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg DJM, Hoeben RC, Coffey M, Loghmani H, Verdegaal EME, Welters MJP, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Cancer Immunol Res. 2024 Mar 4;12(3):334-349. doi: 10.1158/2326-6066.CIR-23-0480. Cancer Immunol Res. 2024. PMID: 38194598 Free PMC article.
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, Colombo A, Coffey M, Fernandez Hernandez E, Chen X, Nuovo GJ, Carew JS, Mohrbacher AF, Fields P, Kuhn P, Siddiqi I, Merchant A, Kelly KR. Nawrocki ST, et al. Clin Cancer Res. 2023 Dec 15;29(24):5087-5103. doi: 10.1158/1078-0432.CCR-23-0229. Clin Cancer Res. 2023. PMID: 37812476 Free PMC article. Clinical Trial.
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.
Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Krill-Jackson E, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD. Clark AS, et al. Clin Cancer Res. 2025 Jul 1;31(13):2655-2662. doi: 10.1158/1078-0432.CCR-24-2701. Clin Cancer Res. 2025. PMID: 40300087 Free PMC article. Clinical Trial.
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
Dona AA, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, Zhu Y, Moloudizargari M, Sharma P, Napolitano O, Winchester J, Chowdhury A, Pozhitkov A, Sanchez JF, Vahed H, Marcucci G, Coffey M, Nuovo G, Sborov DW, Pichiorri F, Hofmeister CC. Dona AA, et al. J Hematol Oncol. 2025 Jan 20;18(1):1. doi: 10.1186/s13045-024-01645-3. J Hematol Oncol. 2025. PMID: 39828738 Free PMC article. Clinical Trial.
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Berkeley RA, et al. Cancer Immunol Res. 2018 Oct;6(10):1161-1173. doi: 10.1158/2326-6066.CIR-18-0309. Epub 2018 Sep 12. Cancer Immunol Res. 2018. PMID: 30209061 Free article.
50 results